ACAD as reported
ACADIA Pharmaceuticals Inc. reported $1.10B of revenue over the trailing twelve months, +9.9% on the year before. 10 reported series are charted on this page, each one as filed.
$1.10B
Revenue, trailing twelve months · to Q1 2026 · +9.9% against the twelve months before
- Net Income
- $376M
Net Income · +64% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $114M
Free Cash Flow · +23% year on year · trailing twelve months to Q1 2026
- Op Margin
- 7.4%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.10B | +9.9% | Q1 2026 |
| Net Income | $376M | +64% | Q1 2026 |
| EPS | $2.21 | +61% | Q1 2026 |
| Gross Margin | 91% | n/a | Q1 2026 |
| Op Margin | 7.4% | n/a | Q1 2026 |
| Net Margin | 33% | n/a | Q1 2026 |
| ROE | 29% | n/a | Q1 2026 |
| ROA | 22% | n/a | Q1 2026 |
| Free Cash Flow | $114M | +23% | Q1 2026 |
| P/E | 13.4 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ACADIA Pharmaceuticals Inc. (ACAD) - Revenue & ProfitRevenue & ProfitACADIA Pharmaceuticals Inc. (ACAD)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com